Enabling precision therapy through dermatologic prophylaxis: lessons from COCOON
The treatment landscape for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) has undergone a transformative shift in 2025. Moving from single-agent osimertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI) established by the original FLAURA trial, to an intensified first-line (1L) therapy. The two combination strategies include osimertinib and chemotherapy, based on the FLAURA2 study, and the MARIPOSA trial with amivantamab, an intravenous EGFR-MET (EGFR-Mesenchymal epithelial transition factor) bispecific antibody, in combination with lazertinib, an oral third-generation EGFR TKI, as 1L combination therapy (1-3). In both trials, the combination treatment was compared to the standard of care osimertinib. Amivantamab and lazertinib in the 1L setting demonstrated an overall survival advantage, redefining expectations for long-term disease control in this molecular subset. This survival advantage was accompanied by a high incidence of dermatologic adverse events (AEs), suggesting that toxicity may represent a key limiting factor in sustained treatment delivery (3). In this context, the COCOON trial addresses the critical question of proactive dermatologic AE management (4). In this commentary, we have primarily focused on the role of dermatological prophylaxis as an enabling component of treatment delivery with 1L amivantamab and lazertinib in advanced NSCLC.
Dermatologic toxicities associated with EGFR-directed therapies are not merely cosmetic inconveniences, but can cause significant impacts on quality of life (QOL) (5-7). In the MARIPOSA trial, the dermatologic AE rate was 86%, with one-third of these AEs leading to treatment interruptions and dose modifications (3). The COCOON study provides compelling evidence that an enhanced prophylactic dermatologic management approach can meaningfully reduce clinically significant EGFR-related skin toxicities. Compared with standard-of-care (SOC) dermatologic management, which reflected heterogeneous local clinical practices, the COCOON regimen of prophylactic antibiotics, chlorhexidine wash and a ceramide-based lotion led to a nearly 50% decrease in the incidence of grade 2 or higher dermatologic AEs along with delayed time to first toxicity. The observed benefits were more pronounced for events involving the face, body and scalp. These notable findings also align with the known pathophysiology of the EGFR TKI-induced skin rash and the prophylactic efficacy of tetracycline antibiotics, which have anti-inflammatory properties in addition to their antimicrobial effects, as previously established in studies with panitumumab (5). Additionally, by utilizing the validated Skindex-16 instrument, the trial reported a markedly reduced negative impact on patients’ skin-related QOL with the COCOON regimen (4). The early and dramatic least-squares (LS) mean change from the baseline (approximately 7 for the COCOON versus 25 for the standard arm) at the first assessment translates into a notable difference in how patients feel and perform their daily activities.
The COCOON trial primarily focused on prophylactic dermatological AEs however, it also addressed high risk of venous thromboembolism (VTE). Patients with advanced NSCLC are also at risk of developing VTE, which is a significant cause of morbidity and mortality. The incidence increases with systemic treatment, reaching up to 13% in the first 6 months, as reported in the literature (8). The COCOON trial reported VTE incidence of 5% in early 4 months with prophylactic anticoagulation. Overall, the enhanced prophylactic management arm noted sustained benefits at 6 months without compromising treatment efficacy. Most importantly, these benefits translated into meaningful improvements in patient-reported outcomes (PROs), metrics that increasingly serve as surrogate indicators of long-term treatment tolerability and adherence—through reduced impact on function, emotional well-being, and symptom burden (4).
The COCOON study also highlighted persistent gaps. Unfortunately, rates of paronychia were similar between the enhanced dermatologic management and standard management arms. This finding underscores the need for continued innovation, including regimen refinement, earlier intervention strategies, and patient-specific tailoring based on tolerance and risk factors. Previous studies evaluated different interventions to reduce the incidence of dermatologic AEs from EGFR inhibitors, however no standard protocol has been established. Table 1 summarizes studies utilizes various preventive strategies for anti-EGFR therapy related skin toxicities in lung cancer.
Table 1
| Ref. | EGFR inhibitor | Control arm present (yes/no) | Preventive treatment | Outcome |
|---|---|---|---|---|
| Fuggetta et al. [2019] (9) | Afatinib | No | Topical 1.5% polydatin-based cream twice a day, every day and SPF 30 UVA/UVB sunscreen, prior to the first dose of afatinib and continue for at least 3 months | Mean duration of treatment was 6.4 months. Incidence of all grade skin rash was 41.2%, grade 2 rash was 20.60%, and grade 3 rash was not observed |
| Melosky et al. [2016] (6) | Erlotinib | Yes | Minocycline 200 mg/day and skin moisturizers 4 weeks vs. reactive treatment only vs. no treatment | Prophylactic minocycline significantly lengthened the time to most severe grade of skin reaction, however no reduction in the overall skin reaction over reactive treatment |
| Arrieta et al. [2015] (10) | Afatinib | Yes | Prophylactic tetracycline 250 mg twice a day for 4 weeks with reactive treatment including moisturizers, sunscreen and topical steroids vs. only reactive treatment | Incidence of all grade skin rash and grade 2 and above rash was less frequent in tetracycline arm (44.5% vs. 75.6%; P=0.046 and 15.6% vs. 35.6%; P=0.030). No difference was found in paronychia, xerosis, mucositis, and folliculitis |
| Deplanque et al. [2016] (11) | Erlotinib | Yes | Prophylactic doxycycline 400 mg/day for four months (with erlotinib) vs. no prophylaxis | Reduced folliculitis (P=0.117) and all grade severe skin reactions (P<0.001) with prophylactic doxycycline |
| Lu et al. [2021] (12) | EGFR TKIs | Yes | 0.25% topical betaxolol solution twice a day vs. no prophylactic treatment | Preemptive treatment reduces the cumulative incidence of paronychia (P<0.01) |
| Jatoi et al. [2008, 2011] (13,14) | Cetuximab | Yes | Prophylactic tetracycline 500 mg twice daily for 28 days vs. placebo | Prophylactic tetracycline did not reduce the incidence of skin rash or its severity, compared to the placebo (82% vs. 75%; P=0.56) |
| Iimura et al. [2018] (15) | EGFR TKIs (gefitinib, erlotinib, afatinib, osimertinib) | No | All patients were prescribed a skin care regimen (sunscreen, moisturizers, 1% hydrocortisone). Concomitant NSAIDs in 24.5% of the patient cohort | Co-administration of NSAIDs was preventive (adjusted HR =0.149; P=0.004) |
EGFR, epidermal growth factor receptor; HR, hazard ratio; NSAIDs, non-steroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer; Ref., References; SPF 30 UVA/UVB, sun protection factor 30 ultraviolet A/ultraviolet B; TKI, tyrosine kinase inhibitor.
A major methodological challenge in interpreting the COCCON trial is the lack of clarity about the comparator SOC arm. Patients randomized to the SOC arm were managed according to local clinical practice without a mandated preventive regimen. While this approach embodies real-world heterogeneity, it also introduces substantial variability, complicating interpretation. As Cho et al. noted, 28% of patients in the standard arm received some form of prophylactic intervention, most commonly sunscreen and simple moisturizers, with only a small subset receiving topical or oral antibiotics or steroids. This ad hoc prophylaxis in the comparator arm may bias the results, indicating that the true benefit of the COCCON regimen could be greater than reported. Nevertheless, in an era when some degree of skin care is routine, defining an appropriate control group is still a continual challenge.
The open-label design, necessitated by the nature of the intervention, poses possible bias that warrants detailed consideration. Both patients and investigators were aware of treatment allocation, which may have influenced behaviour in fine yet meaningful ways. Patients in the standard arm, having consented to a trial focused on skin toxicity, may have been more attentive to skin changes than typical patients outside a study setting, possibly increasing event reporting. Conversely, investigators may have subconsciously graded events more leniently in the COCCON arm, knowing these patients received intensive prophylaxis. Although the use of validated grading criteria and consistent training mitigates this concern, the possibility of ascertainment bias cannot be fully excluded. This stresses the importance of objective PROs, which corroborate clinician-graded findings and improve the credibility of the overall conclusions. In the future, broader QOL endpoints may benefit from more detailed analysis.
The limited median follow-up of 7.1 months, while sufficient to meet the primary endpoint focused on the first 12 weeks, elicits important questions regarding the durability of the observed benefit. Extended observation would allow for a stronger analysis of how dermatological management influences long-term therapy adherence and survival outcomes. Additionally, the prophylactic use of tetracycline antibiotics for 12 weeks elicits worries relating to potential downstream consequences, particularly antimicrobial resistance. Although the study reports no increase in infections or liver toxicity with prolonged tetracycline exposure, the follow-up duration is insufficient to assess long-term ecological effects on the microbiome or the risk of carriage of resistant organisms. Given the increasing emphasis on antibiotic stewardship, clinicians must balance the clear short-term benefit of rash prevention against possible population-level risk of promoting resistance. This consideration is especially relevant for patients who may require repeated antibiotic courses for infections during cancer treatment.
The broader implications of the COCOON trial are substantial. The COCOON regimen is intentionally pragmatic, using inexpensive, widely accessible medications that can be initiated at the start of treatment without specialist referral. In healthcare settings with limited specialist dermatology access and infrequent patient visits, proactive prophylaxis provides a practical approach to reducing treatment interruptions, maintaining dose intensity, and minimizing unscheduled visits or hospitalizations. Standardizing such regimens across clinical practices can streamline patient education, empower nursing teams, and enhance consistency in care delivery. The COCOON trial offers randomized, prospective evidence supporting the routine integration of prophylactic dermatologic management with first-line amivantamab and lazertinib. As combination strategies with superior survival outcomes replace single-agent TKI therapies, toxicity prevention should be considered an essential component of regimen design rather than an optional aspect of supportive care.
Effective toxicity prevention is essential for realizing the full therapeutic potential of contemporary EGFR-directed combination therapies. The COCOON trial establishes a new benchmark for supportive care research by demonstrating that proactive, evidence-based dermatologic management can significantly enhance treatment persistence and serve as a critical determinant of clinical benefit with combination therapy. As treatment paradigms continue to evolve, integrating toxicity prevention strategies into regimen design should be considered indispensable rather than optional.
Acknowledgments
None.
Footnote
Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article has undergone external peer review.
Peer Review File: Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0456/prf
Funding: None.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0456/coif). J.R. has served on an advisory board for AstraZeneca, Lilly, Merck and Novartis. D.B. has received honoraria from Johnson and Johnson, AstraZeneca, Merck, Boehringer Ingelheim, Pfizer and Amgen. The other authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41-50. [Crossref] [PubMed]
- Jänne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2026;394:27-38. [Crossref] [PubMed]
- Hayashi H, Cho BC, Kim YJ, et al. Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. Lung Cancer 2026;214:109305. [Crossref] [PubMed]
- Cho BC, Li W, Spira AI, et al. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. J Thorac Oncol 2025;20:1517-30. [Crossref] [PubMed]
- Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7. [Crossref] [PubMed]
- Melosky B, Anderson H, Burkes RL, et al. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol 2016;34:810-5. [Crossref] [PubMed]
- Petrelli F, Borgonovo K, Cabiddu M, et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 2016;175:1166-74. [Crossref] [PubMed]
- Khorana AA, Palaia J, Rosenblatt L, et al. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J Immunother Cancer 2023;11:e006072. [Crossref] [PubMed]
- Fuggetta MP, Migliorino MR, Ricciardi S, et al. Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. Scientifica (Cairo) 2019;2019:9136249. [Crossref] [PubMed]
- Arrieta O, Vega-González MT, López-Macías D, et al. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. Lung Cancer 2015;88:282-8. [Crossref] [PubMed]
- Deplanque G, Gervais R, Vergnenegre A, et al. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. J Am Acad Dermatol 2016;74:1077-85. [Crossref] [PubMed]
- Lu CW, Wang TY, Yen CF, et al. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. Int J Dermatol 2021;60:179-84. [Crossref] [PubMed]
- Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-53. [Crossref] [PubMed]
- Jatoi A, Dakhil SR, Sloan JA, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer 2011;19:1601-7. [Crossref] [PubMed]
- Iimura Y, Shimomura H, Yasu T, et al. NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients. Int J Clin Pharmacol Ther 2018;56:551-4. [Crossref] [PubMed]
